Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis세 번째 및 네 번째 BNT162b2 mRNA COVID-19 부스터 및 SLE 및 류마티스 관절염 환자의 면역 반응과 관련된 인자의 면역원성Article Published on 2022-07-012022-09-11 Journal: Lupus science & medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] adenoviral vector Administered anti-RBD Anti-RBD IgG Arthritis benefit BNT162b2 BNT162b2 mRNA booster booster dose booster vaccination cellular Cellular immune response COVID-19 domain enrolled evaluate Factor heterogenous humoral Humoral response IgG immune response immunogenicity immunosuppressive inactivated Inactivated vaccine initial Lupus lupus erythematosus Lupus Erythematosus, Systemic mRNA vaccines Neutralising activity occurred omicron Omicron variant Patient positive raised RBD RBD IgG registration number rheumatoid arthritis significantly SLE systemic titre vaccination Vaccine variant was done were given [DOI] 10.1136/lupus-2022-000726 PMC 바로가기 [Article Type] Article
SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy전신 경화증 환자의 SARS-CoV-2 백신: 질병 하위 유형 및 치료의 영향Clinical Trial Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] affected affecting anti-SARS-CoV-2 Antibody Response baseline comparable Control controls CoronaVac disease dose Factor first dose Follow-up Frequency immunogenicity immunosuppressive inactivated individual Interstitial lung disease majority median age MMF moderate monotherapy Most patient Multiple mycophenolate neutralizing antibody Participants Patient Prospective Study regression analysis respiratory safety profile SARS-CoV-2 SARS-CoV-2 vaccine Seroconversion Side-effect subgroup of patients Systemic sclerosis therapy Trial vaccination Vaccine vaccine response were assessed [DOI] 10.1093/rheumatology/keab886 PMC 바로가기 [Article Type] Clinical Trial
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions실생활에서 자가면역 염증성 류마티스 질환 환자의 코로나19 예방접종에 대한 체액 및 세포 반응Observational Study Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI anti-S antibody anti-S IgG approved Autoimmune cellular cellular response cellular T-cell response condition conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine effective Efficacy evaluated highest humoral Humoral response IgG antibody Immunosuppression immunosuppressive Immunosuppressive medication Inflammatory inhibitors interferon-γ knowledge medication mRNA vaccination mRNA vaccine negative correlation non-responder Patient patients rheumatic disease Rheumatic diseases risk RTX SARS-CoV-2 spike protein significantly lower subgroup of patient T-cell T-cell Response the S1 subunit therapy TNF Tocilizumab vaccination vaccination efficacy vaccination responses Vaccine were measured [DOI] 10.1093/rheumatology/keac089 PMC 바로가기 [Article Type] Observational Study
The Cyclophilin-Dependent Calcineurin Inhibitor Voclosporin Inhibits SARS-CoV-2 Replication in Cell Culture사이클로필린 의존성 칼시뉴린 억제제 보클로스포린은 세포 배양에서 SARS-CoV-2 복제를 억제합니다Article Published on 2022-06-242022-09-11 Journal: Transplant International [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antiviral activity Antiviral assays assays benefit binding calcineurin calcineurin inhibitors can not clinical evaluation CNI Combination Comorbidity Compound compounds Concentration coronavirus Coronaviruses Course COVID-19 cyclophilin cyclosporin cyclosporin A EC50 value EC50 values evaluated experiments False-positive results human Calu-3 cell human Calu-3 cells Immunosuppressant immunosuppressants Immunosuppression immunosuppressive increased risk Infection inhibitor Interference kidney kidney transplant recipients Kidney transplantation lab progeny protocol recipient reduced reducing regimen reported RNA viruses SARS-CoV-2 SARS-CoV-2 replication severe acute respiratory syndrome Coronavirus tacrolimus voclosporin voclosporin. with COVID-19 [DOI] 10.3389/ti.2022.10369 PMC 바로가기 [Article Type] Article
Who is pausing immunosuppressive medication for COVID-19 vaccination? Results of an exploratory observational trialObservational Study Published on 2022-06-222022-10-05 Journal: European Journal of Medical Research [Category] COVID19(2023년), SARS, 임상, [키워드] addition age asked baseline Characteristics condition contribute COVID-19 COVID-19 vaccination drug Drug adherence Drug compliance Evidence exploratory Gender immunization immunogenicity Immunosuppressed Immunosuppression immunosuppressive Immunosuppressive medication individual lack medication over participant Participants Patient Person physician prospective observational study questionnaire receive receiving Registered reported Result risk SARS-CoV-2 SARS-CoV-2 vaccination significantly more therapy Trial underlying disease vaccination women worsening [DOI] 10.1186/s40001-022-00727-7 PMC 바로가기 [Article Type] Observational Study
Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency공통 가변성 면역 결핍증에서 2개의 ChAdOx1 nCoV-19 후 BNT162b2 부스팅에 의해 유도된 특정 항체 및 T-세포 반응Article Published on 2022-06-172022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 immunoglobulin Anti-spike antibody autologous BNT162b2 BNT162b2 vaccine booster vaccination CD19 CD19+ CD3+ CD3+CD4+ CD3+CD8+ CD4+ CD45 CD45+ CD8+ Cell cell count cell counts cell-mediated response ChAdOx1 ChAdOx1 nCoV-19 changes in common common variable immunodeficiency common variable immunodeficiency (CVID) Control Coronavirus-2 COVID-19 infection cumulative cut-off value CVID decrease ELISPOT ELISpot assay evaluated except for flow cytometric healthy control healthy controls healthy individual healthy individuals humoral IFN-γ IFN-γ ELISPOT IFN-γ ELISpot assay IFN-γ producing T cells immune response immunodeficiency Immunoglobulin Immunoglobulin G immunosuppressive immunosuppressive therapy individual interferon interferon-γ Killer cell less Lymphocytes measure morbidity natural killer natural killer cell not different not significant Patient patients positive Primary Immunodeficiency producing protein S raised receiving response Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 shown Side effects significant difference significant differences significantly significantly lower Specific statistically stem cell Stem cell transplantation T cell T cell response T cells tested therapy These data vaccination Vaccinations variable virus-specific T cell virus-specific T-cell with COVID-19 [DOI] 10.3389/fimmu.2022.907125 PMC 바로가기 [Article Type] Article
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients조혈모세포이식 및 CAR T-세포 치료 수혜자의 SARS-CoV-2 예방접종에 대한 면역반응Article Published on 2022-06-162022-09-12 Journal: Journal of Hematology & Oncology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition affected Analysis Antigen booster dose CAR CAR-T cellular response chimeric antigen receptor Chimeric antigen receptor T-cell (CAR-T) therapy conducted COVID-19 vaccine Efficacy evaluate healthy individuals Hematopoietic stem cell Hematopoietic stem cell transplantation (HSCT) HSCT HSCT recipients humoral immune response immunosuppressive increased risk indicated Lymphocyte count outcome Patient receptor recipient recipients required Research response to vaccination SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination Seroconversion significantly significantly higher Stem cell transplantation T-cell therapy Undetermined vaccination Vaccination strategy [DOI] 10.1186/s13045-022-01300-9 PMC 바로가기 [Article Type] Article
Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine항중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 스파이크 단백질 항체 역가 및 BNT162b2 백신 접종 후 의료 종사자의 중화 활성과 관련된 요인Observational Study Published on 2022-06-102022-09-12 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] acute respiratory syndrome Adverse reaction age All participant Analysis anti-SARS-CoV-2 IgM antibody Antibody titer blood sample BNT162b2 vaccine chemiluminescent immunoassay conducted coronavirus Cutoff elevated Enrollment Factor female Fever first dose Fukushima healthcare worker hospital identify IgG IgG antibody IgG antibody titer IgM Immunoglobulin Immunoglobulin G immunosuppressive increase in individuals intake Japan joint lack Local medication N-protein Neutralizing activity Neutralizing antibody titer of BNT162b2 Pain participant Pfizer-BioNTech Prevent Protein response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose Sex significantly Spike protein the SARS-CoV-2 vaccination Vaccine vaccine doses was obtained were measured [DOI] 10.1371/journal.pone.0269917 PMC 바로가기 [Article Type] Observational Study
Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation동종 조혈 세포 이식 후 182명의 환자에서 mRNA SARS-CoV-2 백신 접종에 대한 항체 반응Article Published on 2022-06-012022-09-12 Journal: Transplant infectious disease : an official journa [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Allogeneic Allogeneic hematopoietic cell transplantation Antibody titer asked Care Cell cell transplantation Characteristics complications disease Elecsy evaluate evaluated excluded Factor follow-up visits high risk identify immune immunosuppressive infection with SARS-CoV-2 initial Lymphocyte count majority malignancy mRNA mRNA vaccination mRNA vaccine Patient patient cohort patients post-transplant care. Previous studies proportion risk factor Roche SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination Sex significantly Stem cell transplantation therapy Treatment trials U/mL underlying disease vaccination vaccination efficacy was measured while [DOI] 10.1111/tid.13828 PMC 바로가기 [Article Type] Article
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases메토트렉세이트를 일시 중단하면 류마티스 질환이 있는 노인 환자에서 COVID-19 예방 접종의 면역원성이 향상됩니다.Article Published on 2022-06-012022-09-12 Journal: Annals of the rheumatic diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] age antibody Antibody Response Autoimmune Autoimmune diseases control group correlated COVID-19 COVID-19 vaccination Critical cut-off Elderly patient fixed greater humoral immune response immune response immunosuppressive Immunosuppressive medication IMPROVE medication methotrexate MTX neutralising neutralising antibody nine Older Patient patients older reduce regimen Retrospective study rheumatic disease SARS-CoV-2 antibody SARS-CoV-2 vaccination second vaccination significantly significantly higher significantly lower the antibody response therapy vaccination were measured [DOI] 10.1136/annrheumdis-2021-221876 PMC 바로가기 [Article Type] Article